Clinical Orthopaedics and Related Research: September 2010 - Volume 468 - Issue 9 - p 2392–2396 doi: 10.1007/s11999-010-1325-5 SYMPOSIUM: COMPLICATIONS OF HIP ARTHROPLASTY

Retrospective Analysis of Infection Rate After Early Reoperation in Total Hip Arthroplasty

Darwiche, Hussein, MD1; Barsoum, Wael, K., MD1; Klika, Alison, MS1, a; Krebs, Viktor, E., MD1; Molloy, Robert, MD1
Hip

Background Infection is a devastating complication of total hip arthroplasty (THA). Unavoidable reoperation during the acute recovery phase of hip arthroplasty has the potential for an increased infection rate but the risk is not well established nor is the fate of these infected hips.

 

Questions/purposes We therefore report the infection rate for patients undergoing THA who returned to the operating room within 90 days of his or her index procedure for any surgical intervention on the same hip.

 

Methods We identified 60 patients undergoing THA referred to or treated at our institution who required an unplanned and unavoidable return to the operating room during the acute recovery phase. The complications of the initial surgery that resulted in reoperation included instability, periprosthetic fracture, retained hardware, and nerve exploration. We then retrospectively reviewed the medical records to determine the infection rate and implant survivorship. The minimum followup was 1 month (average, 3.7 years; range, 1 month to 7 years) and included all patients who required resection before a minimum 2-year followup.

 

Results The infection rate for this cohort was 20 of 60 (33%). Six of these 20 retained their implants at 2 years after the reoperation and were considered infection-free. Two-stage reimplantation or resection was eventually performed in 14 of the infected patients.

 

Conclusions A high percentage of patients undergoing THA developed a deep infection after unavoidable reoperation during the acute recovery phase. The reasons for the reoperations were potentially modifiable complications and situations that deserve further investigation to delineate protocols to minimize the risk of infection in these patients.

 

Level of Evidence Level IV, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.


Link to article